Toms River, NJNCT07441642Now EnrollingIRB Ready

Geographic Atrophy Secondary to Age-related Macular Degeneration Clinical Trial in Toms River, NJ

Access cutting-edge geographic atrophy secondary to age-related macular degeneration treatment through this clinical trial at a research site in Toms River. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Toms River location

Preparing your pre-screening questions…

Expert Care in Toms River

Access geographic atrophy secondary to age-related macular degeneration specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related geographic atrophy secondary to age-related macular degeneration treatment provided free

Apply for This Toms River Location

Check if you qualify for this geographic atrophy secondary to age-related macular degeneration clinical trial in Toms River, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Toms River

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Toms River site if eligible
  4. 4Begin participation

About This Geographic Atrophy Secondary to Age-related Macular Degeneration Study in Toms River

To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Male or female participants ≥ 50 years of age.
A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.
Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)
If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2
Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy
ETDRS BCVA ≥ 35 letters (20/200) in the study eye.

Exclusion Criteria

A history of, or current evidence of, choroidal neovascularization (exudative MNV) in either eye, as determined by the central reading center on multimodal imaging at screening.
Previous cell or gene therapy in either eye.
Macular atrophy in either eye due to a cause other than AMD, such as Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.
Intraocular surgery, including cataract and vitreoretinal surgery, in the study eye within 3 months prior to Baseline.
Presence of significant media opacity, eye movement disorder (nystagmus), severe ptosis, extraocular motility restriction or head tremor, which in the opinion of the investigator, would prevent adequate fundus visualization or interfere with retinal imaging data quality. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Toms River?

Yes, this clinical trial (NCT07441642) has an active research site in Toms River, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Geographic Atrophy Secondary to Age-related Macular Degeneration Treatment Options in Toms River, NJ

If you're searching for geographic atrophy secondary to age-related macular degeneration treatment options in Toms River, NJ, this clinical trial (NCT07441642) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Toms River research site is actively enrolling participants for this clinical trial. You'll receive care from experienced geographic atrophy secondary to age-related macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all geographic atrophy secondary to age-related macular degeneration clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Toms River, NJ

See all rheumatoid arthritis clinical trials recruiting in Toms River — not just this study.

Browse Rheumatoid Arthritis Trials in Toms River →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMacular Degeneration TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Toms River?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Toms River, NJ